<DOC>
	<DOCNO>NCT00795002</DOCNO>
	<brief_summary>This randomized phase II trial study two different schedule alvocidib compare well work give together cytarabine mitoxantrone treat patient newly diagnose acute myeloid leukemia . Drugs use chemotherapy , alvocidib , cytarabine , mitoxantrone , work different way stop growth cancer cell , either kill cell stop dividing . It yet know schedule alvocidib effective give together cytarabine mitoxantrone treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Alvocidib , Cytarabine , Mitoxantrone Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare efficacy two different schedule ( bolus v `` hybrid bolus-infusion '' ) alvocidib follow cytarabine mitoxantrone hydrochloride patient newly diagnose acute myeloid leukemia ( AML ) poor-risk feature . SECONDARY OBJECTIVES : I . To compare toxicity regimens . II . To determine disease-free survival overall survival patient demonstrate response regimen . III . To compare pharmacokinetics alvocidib administer two different schedule ( bolus v `` hybrid bolus-infusion '' ) . IV . To describe alvocidib-induced alteration AML blast cell expression select target mRNA protein . V. To describe alvocidib-induced alteration AML blast cell growth kinetic parameter . OUTLINE : This multicenter study . Patients stratify accord antecedent hematologic disorder &gt; = 6 month duration prior transformation acute myeloid leukemia ( AML ) prior antecedent therapy myelodysplastic syndrome myeloproliferative disorder . Patients randomize 1 2 treatment arm . ARM I : Patients receive alvocidib IV 1 hour day 1-3 , cytarabine IV continuously 72 hour day 6-8 , mitoxantrone hydrochloride IV 60-120 minute day 9 . ARM II : Patients receive alvocidib IV 30 minute follow alvocidib IV 4 hour day 1-3 . Patients also receive cytarabine mitoxantrone hydrochloride arm I . Patients achieve partial complete response ( CR ) first course treatment may receive second course treatment 35-63 day follow blood count recovery and/or undergo allogeneic bone marrow transplantation . Patients &gt; = 50 year age ( 8 ; 21 ) , inv ( 16 ) , ( 16 ; 16 ) AML achieve CR first course treatment may receive 3-4 course high-dose cytarabine consolidation therapy . Bone marrow and/or blood sample collect baseline periodically study correlative laboratory study , include pharmacokinetic study liquid chromatography tandem mass spectrometry , analysis blast cell growth kinetic parameter flow cytometry , blast cell expression select target mRNA protein quantitative RT-PCR western blotting . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Pathologically confirm newly diagnose acute myeloid leukemia ( AML ) meeting follow criterion : Subtypes M0 , M1 , M2 , M47 No acute promyelocytic leukemia ( M3 ) At least 50 year age OR &gt; = 18 year age &gt; = 1 follow poorrisk disease feature : Antecedent hematologic disorder , include myelodysplastic syndrome ( MDS ) relate AML prior myeloproliferative disorder ( MPD ) Treatmentrelated AML , AML trilineage dysplasia Myeloid sarcoma , myeloid proliferation relate Down Syndrome , blastic plasmacytoid dendritic cell neoplasm AML trilineage dysplasia AML adverse cytogenetics ( defined 5/5q ; 7/7q ; abnormal 3q , 9q , 11q , 20q , 21q , 17p ; [ 6 ; 9 ] ; [ 9 ; 22 ] ; trisomy 8 ; trisomy 13 , complex karyotype [ &gt; = 3 unrelated abnormality ] ) , No hyperleukocytosis &gt; = 50,000 blasts/uL ( leukapheresis hydroxyurea allow cytoreduction immediately prior first dose alvocidib ) No active CNS leukemia ECOG performance status 02 Serum creatinine = &lt; 2.0 mg/dL ALT/AST = &lt; 5 time upper limit normal Bilirubin = &lt; 2.0 mg/dL Not pregnant nursing Negative pregnancy test No active uncontrolled infection Infection active treatment allow provide control antibiotic No lifethreatening illness No mental deficit and/or psychiatric history would preclude give informed consent follow study requirement At least 24 hour since prior leukapheresis hydroxyurea cytoreduction Prior noncytotoxic therapy ( e.g. , thalidomide lenalidomide , interferon , cytokine , lowdose 5azacytidine , lowdose cytoxan ) MDS MPD allow Prior chemotherapy bone marrow/stem cell transplantation nonAML malignancy allow No prior alvocidib No concurrent chemotherapy , radiotherapy , immunotherapy No concurrent investigational commerciallyavailable antitumor therapy AML LVEF &gt; = 45 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>